Latest Conference Coverage


Mobile Stroke Units Superior to Standard Management in 90-Day Stroke Outcomes

Mobile Stroke Units Superior to Standard Management in 90-Day Stroke Outcomes

March 17th 2021

Treatment with tPA within 0 to 60 minutes of last known normal occurred for 33% of patients on mobile stroke units, compared to 3% who received standard management.


Spencer Hutto, MD

Investigating Causes of CNS Demyelination: Spencer Hutto, MD

March 17th 2021

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the need for follow-up with patients long-term after TNFα inhibitor treatment.


Apitegromab Demonstrates Safety, Efficacy in Spinal Muscular Atrophy

Apitegromab Demonstrates Safety, Efficacy in Spinal Muscular Atrophy

March 17th 2021

Scholar Rock noted that the topline results from the 52-week treatment period are expected to be announced in the second quarter of 2021.


NeuroVoices: Anne Kever, PhD, on MS Diagnosis Disclosure, Concealment Behaviors

NeuroVoices: Anne Kever, PhD, on MS Diagnosis Disclosure, Concealment Behaviors

March 17th 2021

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.


Ishu Arpan, PT, PhD

The Importance of Identifying Those at Risk of Falling in MS

March 16th 2021

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, also discussed further studies she would like to see conducted in MS falls.


Jerry R. Mendell, MD

Zolgensma Shows Safety and Durability of Efficacy in Long-Term Follow-Ups for SMA Type 1

March 16th 2021

LT-001 and LT-002 followed up patients treated with onasemnogene abeparvovec from the START, STRONG, STR1VE, and STR1VE-EU studies.


COVID-19 and Muscular Dystrophies, and R&D for Rare Disorders: Sharon Hesterlee, PhD

COVID-19 and Muscular Dystrophies, and R&D for Rare Disorders: Sharon Hesterlee, PhD

March 16th 2021

The executive vice president and chief research officer of the MDA offered her perspective on the ongoing conversations about and impact of the pandemic on the care of patients with muscular dystrophies.


Swallowing Function Possibly Nonissue With Nusinersen in Presymptomatic SMA

Swallowing Function Possibly Nonissue With Nusinersen in Presymptomatic SMA

March 16th 2021

At each timepoint, all assessed participants with 3 SMN2 copies and the majority with 2 SMN2 copies were identified by PASA as not being tube fed.


Identifying and Diagnosing Genetic Leukodystrophies as MS Mimics

Identifying and Diagnosing Genetic Leukodystrophies as MS Mimics

March 16th 2021

Alise Carlson, MD, a resident at Cleveland Clinic, discussed her presentation from ACTRIMS Forum 2021 on the misdiagnosis of adult-onset genetic leukodystrophies as multiple sclerosis.


Nusinersen Safety Demonstrated in DEVOTE Phase 2/3 Study in SMA

Nusinersen Safety Demonstrated in DEVOTE Phase 2/3 Study in SMA

March 15th 2021

Treatment with nusinersen demonstrated no clinically meaningful changes in vital signs or clinical laboratory parameters, including urine parameters, in those with spinal muscular atrophy.


High-Dose Risdiplam Results in High Percentage of Event-Free Infants With SMA

High-Dose Risdiplam Results in High Percentage of Event-Free Infants With SMA

March 15th 2021

The high-dose cohort in part 1 of the FIREFISH study also showed that more than 50% of infants could sit without support and more than 90% could feed orally.


Understanding Effects of Diagnosis Disclosure in MS: Anne Kever, PhD

Understanding Effects of Diagnosis Disclosure in MS: Anne Kever, PhD

March 15th 2021

The postdoctoral researcher at Columbia University discussed her abstract from ACTRIMS Forum 2021 on the associations of MS diagnosis disclosure and concealment with anxiety and depression.


Jens Kuhle, MD, PhD

Early Plasma GFAP Lowering Predicts Reduced Disability Worsening Risk in Progressive MS

March 14th 2021

In assessing patients treated with siponimod, researchers also saw that plasma neurofilament light levels slightly predicted a reduced risk of disease worsening.


Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical Care

Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical Care

March 13th 2021

Sharon Hesterlee, PhD, executive vice president and chief research officer, MDA, shares an early look at the MDA's 2021 Virtual Clincial and Scientific Conference, March 15-18.


Daniel Reich, MD, PhD

Anakinra and Tolebrutinib for Chronic Inflammation in MS: Daniel Reich, MD, PhD

March 12th 2021

The senior investigator at the National Institutes of Neurological Disorders and Stroke discussed 2 treatments currently being evaluated for use in multiple sclerosis.


What to Expect from the 2021 MDA Clinical and Scientific Conference: Sharon Hesterlee, PhD

What to Expect from the 2021 MDA Clinical and Scientific Conference: Sharon Hesterlee, PhD

March 12th 2021

The executive vice president and chief research officer of the MDA gave an overview of the upcoming virtual annual meeting and her insight on what to look for.


Next Steps in Improving Autoimmune Encephalitis Care

Next Steps in Improving Autoimmune Encephalitis Care

March 11th 2021

The assistant professor of neurology at Mayo Clinic detailed the areas of autoimmune encephalitis research that need more attention, as well as the diagnostic potential of autoantibody assays.


Yujie Wang, MD

Investigating the 1-Hour Post-Infusion Monitoring Period: Yujie Wang, MD

March 11th 2021

The neurologist from the University of Washington Medical Center discussed how the study of natalizumab adverse events came about and the importance of this monitoring period.


Evan Luxenberg, MD

Older Patients With MS Face Additional Risks With Ocrelizumab Treatment

March 10th 2021

The retrospective analysis in patients aged 55 years and older underlines the importance of testing different patient populations.


Stephanie Blandford, MSc

Interleukin-1 Receptor Antagonism and Multiple Sclerosis: Stephanie Blandford, MSc

March 10th 2021

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed further research she would like to see conducted with IL-1RA in MS.


Carlos Perez, MD

African American Patients Have Higher MS Disability Scores Than Hispanic, Caucasian Patients

March 9th 2021

Researchers found that, in an exploratory analysis of 150 patients, African American patients with MS were most likely to become disabled and lose employment.


 Ishu Arpan, PT, PhD

Identifying Those at Risk of Falling in Multiple Sclerosis

March 8th 2021

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, discussed her team’s investigations into identifying patients with MS at risk of falling.


Fatigue Severely Impacts Quality of Life, Work Productivity in MS

Fatigue Severely Impacts Quality of Life, Work Productivity in MS

March 7th 2021

Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.


Ilena George, MD

Prescribing DMT in Radiologically Isolated Syndrome: Ilena George, MD

March 7th 2021

The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.


Understanding the Momentum in the Autoimmune Encephalitis Research Community

Understanding the Momentum in the Autoimmune Encephalitis Research Community

March 5th 2021

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.


African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

March 4th 2021

Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.

© 2024 MJH Life Sciences

All rights reserved.